SBIR-STTR Award

Investigation of a sorbent-based potassium adsorber for the treatment of hyperkalemia induced by traumatic injury and acute kidney injury in austere medicine
Award last edited on: 10/12/2017

Sponsored Program
SBIR
Awarding Agency
DOD : DHA
Total Award Amount
$1,149,798
Award Phase
2
Solicitation Topic Code
DHP16-010
Principal Investigator
Phillip P Chan

Company Information

CytoSorbents Corporation (AKA: CytoSorbents Inc~MedaSorb Technologies Corporation~MedaSorb Technologies Inc)

305 College Road East
Princeton, NJ 08540
   (732) 329-8885
   info@cytosorbents.com
   www.cytosorbents.com
Location: Single
Congr. District: 12
County: Mercer

Phase I

Contract Number: ----------
Start Date: ----    Completed: ----
Phase I year
2016
Phase I Amount
$149,927
Hyperkalemia will clearly continue to be a concern in the treatment of combat casualties. The risk of death from hyperkalemia-induced cardiac arrhythmias is significant in the absence of renal replacement therapy (RRT). Rapid evacuation out of Iraq and Afghanistan ensured that most hyperkalemia occurred further up the evacuation chain, thereby limiting the need for non-RRT hyperkalemia treatment options in austere medicine. In future theaters of operation, the military research community must prepare for prolonged field care and extended evacuation times. One implication of the delay is that complications of combat injury, including life-threatening hyperkalemia, will be more frequently managed in the far forward deployed setting. To address this unmet medical need for the military, we plan to develop a forward care medical devices to treat hyperkalemia. In this study two medical devices will be developed, intra-peritoneal dialysis and intra-abdominal mesh packing devices, to reduce systemic potassium levels in austere medical treatment environments. The benefits of our forward care medical device are three-fold: 1) stabilizes hyperkalemia patients to endure prolonged field care and delayed evacuation, 2) is logistically feasible to implement for field use, and 3) expands hyperkalemia treatment options to include transport on aircraft with limited medical capability.

Phase II

Contract Number: ----------
Start Date: ----    Completed: ----
Phase II year
2017
Phase II Amount
$999,871
Hyperkalemia will clearly continue to be a concern in the treatment of combat casualties. The risk of death from hyperkalemia-induced cardiac arrhythmias is significant in the absence of renal replacement therapy (RRT). Rapid evacuation out of Iraq and Afghanistan ensured that most hyperkalemia occurred further up the evacuation chain, thereby limiting the need for non-RRT hyperkalemia treatment options in austere medicine. In future theaters of operation, the military research community must prepare for prolonged field care and extended evacuation times. One implication of the delay is that complications of combat injury, including life-threatening hyperkalemia, will be more frequently managed in the far forward deployed setting. To address this unmet medical need for the military, we plan to develop a forward care medical devices to treat hyperkalemia. In this study two medical devices will be developed, intra-peritoneal dialysis and intra-abdominal mesh packing devices, to reduce systemic potassium levels in austere medical treatment environments. The benefits of our forward care medical device are three-fold: 1) stabilizes hyperkalemia patients to endure prolonged field care and delayed evacuation, 2) is logistically feasible to implement for field use, and 3) expands hyperkalemia treatment options to include transport on aircraft with limited medical capability.